Vaxcyte Inc
PCVX42.920USD
+1.270+3.05%
Fechamento 11/10, 16:00（ET）Cotações atrasadas em 15 min
5.58BValor de mercado
PerdaP/L TTM
Mais detalhes de Vaxcyte Inc Empresa
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
Informações de Vaxcyte Inc
Código da empresaPCVX
Nome da EmpresaVaxcyte Inc
Data de listagemJun 12, 2020
CEOMr. Grant E. Pickering
Número de funcionários414
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 12
Endereço825 Industrial Road, Ste. 300
CidadeSAN CARLOS
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94070
Telefone16508370111
Sitehttps://vaxcyte.com/
Código da empresaPCVX
Data de listagemJun 12, 2020
CEOMr. Grant E. Pickering
Executivos da empresa Vaxcyte Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
658.46K
-2.69%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
75.59K
-9.54%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
27.26K
-20.53%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
12.60K
-28.82%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.67K
+54.06%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
8.67K
+54.06%
Mr. Jacks Lee
Mr. Jacks Lee
Independent Director
Independent Director
3.04K
--
Mr. John P. Furey
Mr. John P. Furey
Independent Director
Independent Director
3.04K
--
Dr. Olivier Brandicourt
Dr. Olivier Brandicourt
Independent Director
Independent Director
1.15K
--
Dr. Heath Lukatch, Ph.D.
Dr. Heath Lukatch, Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
658.46K
-2.69%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
75.59K
-9.54%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
27.26K
-20.53%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
12.60K
-28.82%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.67K
+54.06%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
8.67K
+54.06%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 31 de out
Atualizado em: sex, 31 de out
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Janus Henderson Investors
11.22%
The Vanguard Group, Inc.
9.39%
RA Capital Management, LP
9.14%
Fidelity Management & Research Company LLC
7.68%
BlackRock Institutional Trust Company, N.A.
6.91%
Outro
55.66%
Investidores
Investidores
Proporção
Janus Henderson Investors
11.22%
The Vanguard Group, Inc.
9.39%
RA Capital Management, LP
9.14%
Fidelity Management & Research Company LLC
7.68%
BlackRock Institutional Trust Company, N.A.
6.91%
Outro
55.66%
Tipos de investidores
Investidores
Proporção
Investment Advisor
46.66%
Investment Advisor/Hedge Fund
34.10%
Hedge Fund
17.68%
Venture Capital
10.87%
Research Firm
2.24%
Bank and Trust
0.84%
Sovereign Wealth Fund
0.75%
Individual Investor
0.68%
Pension Fund
0.51%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
668
148.53M
114.41%
-14.14M
2025Q2
654
150.97M
116.29%
-1.23M
2025Q1
669
149.26M
115.73%
-5.52M
2024Q4
629
143.44M
111.44%
-3.61M
2024Q3
579
138.80M
114.99%
+5.28M
2024Q2
508
125.57M
113.86%
-5.08M
2024Q1
487
122.06M
113.01%
+8.05M
2023Q4
444
106.09M
111.72%
-6.02M
2023Q3
417
110.70M
121.97%
-7.51M
2023Q2
397
109.13M
122.07%
+11.09M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Janus Henderson Investors
14.69M
11.32%
+151.06K
+1.04%
Jun 30, 2025
The Vanguard Group, Inc.
11.97M
9.22%
-48.12K
-0.40%
Jun 30, 2025
RA Capital Management, LP
11.97M
9.22%
-223.16K
-1.83%
Jun 30, 2025
Fidelity Management & Research Company LLC
10.05M
7.74%
-677.06K
-6.31%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
9.05M
6.97%
-85.53K
-0.94%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
6.00M
4.62%
+3.30M
+122.04%
Jun 30, 2025
Wellington Management Company, LLP
4.95M
3.82%
-1.46M
-22.79%
Jun 30, 2025
State Street Investment Management (US)
4.94M
3.81%
+534.55K
+12.13%
Jun 30, 2025
Capital Research Global Investors
4.77M
3.68%
-1.34M
-21.90%
Jun 30, 2025
Paradigm BioCapital Advisors LP
3.37M
2.6%
+1.68M
+98.81%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: qui, 6 de nov
Atualizado em: qui, 6 de nov
Nome
Proporção
Harbor Health Care ETF
4.32%
ALPS Medical Breakthroughs ETF
2.71%
SPDR S&P Biotech ETF
1.38%
Virtus LifeSci Biotech Clinical Trials ETF
0.75%
Direxion Daily S&P Biotech Bull 3X Shares
0.73%
ProShares Ultra Nasdaq Biotechnology
0.48%
Invesco Nasdaq Biotechnology ETF
0.47%
iShares Biotechnology ETF
0.43%
JPMorgan Fundamental Data Science Small Core ETF
0.35%
iShares Russell 2000 Value ETF
0.28%
Ver Mais
Harbor Health Care ETF
Proporção4.32%
ALPS Medical Breakthroughs ETF
Proporção2.71%
SPDR S&P Biotech ETF
Proporção1.38%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.75%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.73%
ProShares Ultra Nasdaq Biotechnology
Proporção0.48%
Invesco Nasdaq Biotechnology ETF
Proporção0.47%
iShares Biotechnology ETF
Proporção0.43%
JPMorgan Fundamental Data Science Small Core ETF
Proporção0.35%
iShares Russell 2000 Value ETF
Proporção0.28%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
